The object of the procurement is narcotics studies for the HUS Diagnostic Center and ISLAB Joint Authority for Well-being (hereinafter referred to as Contracting Entities). Contracting entities procure drug analytics studies that cannot be carried out in their own laboratories for economic or technical reasons.

Procurement is divided into subdivisions. Three (3) suppliers will be selected for each area. If fewer suitable bids are received, all suitable bids will be selected. The selected suppliers shall be ranked in order of priority according to the stated selection criteria.

A tenderer may offer one or more lots and the tenderer may be selected as a service provider for one or more of the lots either for another contracting entity or both.

The comparison of tenders shall be carried out in accordance with this invitation to tender and its supporting documents.

HUS and ISLAB participate in the procurement as contracting entities, and each contracting entity concludes its own framework agreements with the selected service providers.

In all areas, two points are calculated for the tenderer, i.e. the tenderer's score is calculated per contracting entity.

Within the sub-area, two order of priority will be established: one for HUS and the other for ISLAB, and the same tenderers or different tenderers may be selected as service providers for the contracting entities, depending on the points awarded to the tenderers.

The contract is made for a fixed-term contract period of three (3) years. In addition, the acquisition includes two (2) option periods of one (1) year (1 year + 1 year).

Options are about the right of the contracting entity, not the obligation.

The estimated value of the procurement is EUR 10,750,000 (VAT 0%) for the entire contract period.

HUS's share of the value of the contract is EUR 1,700,000 annually and ISLAB's share is EUR 450,000.

The maximum value of the procurement is 11,500,000 (VAT 0%).

The criteria for the object of procurement are described in more detail in the invitation to tender and its accompanying documents.

The minimum requirements for the content of the studies are also described in Appendix 1.

The object of procurement in Lot 2 is drug investigations, extensive screenings U-HuumTOF (21281).

At the time of the offer, the U-HuumTOF sieve shall contain at least the compounds listed in Annex 1, tab U-HuumTOOF.

The examination must also determine the creatinine level of the sample.

The contents of the U-HuumTOF sieve must be indicated in the tender. Details of the method shall be set out in a separate annex.

The reporting limits (cut-offs) of the main analytes of the U -HuumTOF screen shall be indicated, they shall meet the requirements for individual drugs described in Appendix Document 1 on tab U -HuumTOF.

The study shall be conducted entirely by mass spectrometric method. The tender shall describe the features of the method and the measures taken by the tenderer to ensure that the menu is up-to-date and complete.

The criteria and quality comparison criteria set for the U-HuumTOF sieve are described in more detail in the invitation to tender and its appendices.

As a mandatory option, this includes urgent analysis of samples. An urgent sample must be examined and a response given in less than 48 hours. A few urgent samples are examined each year.

The sub-area also includes a U-Amf-Ena follow-up examination as a mandatory option.

The object of procurement in Lot 1 is drug investigations, extensive screens U-HuumLCt, which includes automatic confirmation. A supplier offering a U HuumLCt study must be able to provide the research in question. confirmatory analyses of narcotic and pharmaceutical substances included in the study, which are carried out automatically without a separate request and are included in the price of the study.

The examination must also determine the creatinine level of the sample.

At the time of the offer, the U-HuumLCt screen shall contain at least the compounds listed in Annex 1, tab U-HuumLCt.

The contents of the U -HuumLCt, screens must be indicated in the tender. Details of the method shall be set out in a separate annex.

The reporting limits (cut-offs) of the main analytes in the U-HuumLCt screen shall be indicated, they shall meet the requirements described in Appendix 1 for individual drugs. The study response shall indicate the concentration of the substance/compound for the analytes indicated in Annex 1 on the U -HuumLCt tab.

The study shall be conducted entirely by mass spectrometric method. The tender shall describe the features of the method and the measures taken by the tenderer to ensure that the menu is up-to-date and complete.

The criteria and quality comparison criteria set for the U-HuumLCt screen are described in more detail in the invitation to tender and its appendices.

As a mandatory option, this includes urgent analysis of samples. An urgent sample must be examined and a response given in less than 48 hours. A few urgent samples are examined each year.

The sub-area also includes a U-Amf-Ena follow-up examination as a mandatory option.

The object of procurement in Lot 3 is drug investigations, extensive screenings B-Lääk-Hu (8778).

ISLAB refers to the study as B-HuumLCt. For ISLAB, the minimum and content requirements for the study are the same as for the HUS B-Lääk-Hu study.

The concentrations of substances and compounds in the sample shall be stated in the response to the study. The required substances and compounds are indicated in Annex 1 under tab B -Lääk-Hu. The contents of the B -LääkHu screen must be indicated in the offer.

The reporting limits of the main analytes of the B -Lääk-Hu screen must be indicated, they must meet the requirements described in Appendix document 1 for individual narcotics.

The study shall be conducted entirely by mass spectrometric method. The tender shall describe the features of the method and the measures taken by the tenderer to ensure that the menu is up-to-date and complete.

The criteria and quality comparison criteria set for the B-Lääk-Hu screen are described in more detail in the invitation to tender and its appendices.

As a mandatory option, this includes urgent analysis of samples. An urgent sample must be examined and a response given in less than 48 hours. A few urgent samples are examined each year.

The sub-area also includes a B-Amf-Ena postgraduate study as a mandatory option.

The object of procurement is drug tests and confirmatory studies of urine.

The study-specific requirements are described in more detail in Appendix 1 on the tab Verification studies and in the criteria of the object of the invitation to tender.

This area includes the following studies:

Amphetamine (1810)

- BendiCt (1820)

-BupreCt (1822)

S -CannaCt (1880)

U -FentaCt (9774)

-GHBCt (4612)

S -KokaCt (1884)

LsDCt (4523)

U-MetadCt (1892)

S -OksikCt (9794)

U -OpiaaCt (1902)

S -PregaCt (9777)

TramaCt (4762)

S -TrisykCt (9500)

NukahCt (9775)

MetfeCt (9654)

The Provider may only offer some or all of the studies in this area.

As a mandatory option, this includes urgent analysis of samples. An urgent sample must be examined and a response given in less than 48 hours. A few urgent samples are examined each year.

The provider shall provide urgent research for those studies in this area for which it provides non-urgent research.

The provider offering the U-AmfetCT study shall offer a U Amf-Ena follow-up study as a mandatory option.

The object of the acquisition is S-Metad (4767).

The study shall specify at least Annex 1 (tab 5. S-Metad) concentration of said analytes in the sample.

As a mandatory option, this includes urgent analysis of samples. An urgent sample must be examined and a response given in less than 48 hours. A few urgent samples are examined each year.

The object of the procurement is a confirmatory Me-HuumL-O (8846) study.

The study shall include at least Annex 1 (tab 6. We-HuumL-O) mentioned analysts.

As a mandatory option, this includes urgent analysis of samples. An urgent sample must be examined and a response given in less than 48 hours. A few urgent samples are examined each year.

The object of acquisition of the subdivision must undergo a B-Bendi study of blood.

The study shall specify at least Annex 1 (tab 7. B-Bendi) concentration of mentioned benzodiazepines in the sample.

As a mandatory option, this includes urgent analysis of samples. An urgent sample must be examined and a response given in less than 48 hours. A few urgent samples are examined each year.

The object of procurement in this area is the B-Bupre blood test.

The study shall specify at least Annex 1 (tab 8. B -Bupre) the concentration of said analytes in the sample.

As a mandatory option, this includes urgent analysis of samples. An urgent sample must be examined and a response given in less than 48 hours. A few urgent samples are examined each year.

The object of procurement in this area is the U-Anab test to be determined in the urine.

The study shall include at least Annex 1 (tab 9. U -Anab) mentioned analytes.

As a mandatory option, this includes urgent analysis of samples. An urgent sample must be examined and a response given in less than 48 hours. A few urgent samples are examined each year.